The impact of treatment modality and radiation technique on outcomes and toxicity of patients with locally advanced oropharyngeal cancer

被引:55
作者
Al-Mamgani, Abrahim [1 ]
van Rooij, Peter [2 ]
Verduijn, Gerda M. [1 ]
Mehilal, Robert [1 ]
Kerrebijn, Jeroen D. [3 ]
Levendag, Peter C. [1 ]
机构
[1] Erasmus MC Daniel den Hoed Canc Ctr, Dept Radiat Oncol, NL-3075 EA Rotterdam, Netherlands
[2] Erasmus MC Daniel den Hoed Canc Ctr, Dept Biostat, NL-3075 EA Rotterdam, Netherlands
[3] Erasmus MC Daniel den Hoed Canc Ctr, Dept Otorhinolaryngol, NL-3075 EA Rotterdam, Netherlands
关键词
Oropharyngeal cancer; locally advanced; IMRT; toxicity; head and neck cancer; NECK-CANCER; RADIOTHERAPY; HEAD; CHEMOTHERAPY;
D O I
10.1002/lary.23699
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives/Hypothesis: To investigate the impact of treatment modality and radiation technique on oncologic outcomes and toxicity of patients with locally advanced oropharyngeal cancer (OPC). Study Design: Retrospective analysis of outcomes and toxicity. Methods: Between 2000 and 2011, 204 consecutive patients with locally advanced OPC were treated with definitive (chemo)radiotherapy using 3-dimensional conformal (3DCRT) or intensity-modulated radiotherapy (IMRT). Endpoints were local control (LC), regional control (RC), disease-free survival (DFS), cause-specific survival (CSS), and overall survival (OS), and toxicity. Results: After a median follow-up of 44 months (range 4134), the 5-year Kaplan-Meier estimates of LC, RC, DFS, CSS, and OS were 78%, 92%, 60%, 64%, and 48%, respectively. Grade 3 mucositis and dysphagia (feeding-tube dependency) were reported in 75% and 65%, respectively. The overall incidence of grade 2 and grade 3 late toxicities were 44% and 16%, respectively. Dysphagia and xerostomia were the most frequently reported late toxicity. Chemotherapy was significantly predictive for improved outcomes and increased toxicity. IMRT was significantly correlated with reduced toxicity. Conclusions: Compared to radiation alone, chemoradiotherapy significantly improved oncologic outcomes, but with significantly increased toxicity. Compared to 3DCRT, the introduction of IMRT resulted in a significant reduction of acute and late toxicity with slightly better, or at least comparable, outcomes. Despite the improvements achieved by the implementation of chemo-IMRT, different new strategies to further improve outcome and reduce toxicity need to be thoroughly investigated in prospective, preferably, randomized trials.
引用
收藏
页码:386 / 393
页数:8
相关论文
共 15 条
  • [1] STEREOTACTIC BODY RADIOTHERAPY: A PROMISING TREATMENT OPTION FOR THE BOOST OF OROPHARYNGEAL CANCERS NOT SUITABLE FOR BRACHYTHERAPY: A SINGLE-INSTITUTIONAL EXPERIENCE
    Al-Mamgani, Abrahim
    Tans, Lisa
    Teguh, David N.
    van Rooij, Peter
    Zwijnenburg, Ellen M.
    Levendag, Peter C.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (04): : 1494 - 1500
  • [2] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
    Bonner, James A.
    Harari, Paul M.
    Giralt, Jordi
    Cohen, Roger B.
    Jones, Christopher U.
    Sur, Ranjan K.
    Raben, David
    Baselga, Jose
    Spencer, Sharon A.
    Zhu, Junming
    Youssoufian, Hagop
    Rowinsky, Eric K.
    Ang, K. Kian
    [J]. LANCET ONCOLOGY, 2010, 11 (01) : 21 - 28
  • [3] VALUE OF INTENSITY-MODULATED RADIOTHERAPY IN STAGE IV HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
    Dirix, Piet
    Nuyts, Sandra
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (05): : 1373 - 1380
  • [4] Estimates of cancer incidence and mortality in Europe in 2008
    Ferlay, J.
    Parkin, D. M.
    Steliarova-Foucher, E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (04) : 765 - 781
  • [5] Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer
    Hitt, R
    López-Pousa, A
    Martínez-Trufero, J
    Escrig, V
    Carles, J
    Rizo, A
    Isla, D
    Vega, ME
    Martí, JL
    Lobo, F
    Pastor, P
    Valentí, V
    Belón, J
    Sánchez, MA
    Chaib, C
    Pallarés, C
    Antón, A
    Cervantes, A
    Paz-Ares, L
    Cortés-Funes, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8636 - 8645
  • [6] Are we influencing outcome in oropharynx cancer with intensitymodulated radiotherapy? An inter-era comparison
    Hodge, C. Wesley
    Bentzen, Soren M.
    Wong, Gordon
    Palazzi-Churas, Karen L.
    Wiederholt, Peg A.
    Gondi, Vinai
    Richards, Gregory M.
    Hartig, Gregory K.
    Harari, Paul M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (04): : 1032 - 1041
  • [7] Hyperthermia: a potent enhancer of radiotherapy
    Horsman, M. R.
    Overgaard, J.
    [J]. CLINICAL ONCOLOGY, 2007, 19 (06) : 418 - 426
  • [8] Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: A dose-effect relationship
    Levendag, Peter C.
    Teguh, David N.
    Voet, Peter
    van der Est, Henri
    Noever, Inge
    de Kruijf, Wilhelmus J. M.
    Kolkman-Deurloo, Inger-Karine
    Prevost, Jean-Briac
    Poll, Johan
    Schmitz, Paul I. M.
    Heijmen, Ben J.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2007, 85 (01) : 64 - 73
  • [9] Reducing Xerostomia After Chemo-IMRT for Head-and-Neck Cancer: Beyond Sparing the Parotid Glands
    Little, Michael
    Schipper, Matthew
    Feng, Felix Y.
    Vineberg, Karen
    Cornwall, Craig
    Murdoch-Kinch, Carol-Anne
    Eisbruch, Avraham
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (03): : 1007 - 1014
  • [10] Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial
    Nutting, Christopher M.
    Morden, James P.
    Harrington, Kevin J.
    Urbano, Teresa Guerrero
    Bhide, Shreerang A.
    Clark, Catharine
    Miles, Elizabeth A.
    Miah, Aisha B.
    Newbold, Kate
    Tanay, MaryAnne
    Adab, Fawzi
    Jefferies, Sarah J.
    Scrase, Christopher
    Yap, Beng K.
    A'Hern, Roger P.
    Sydenham, Mark A.
    Emson, Marie
    Hall, Emma
    [J]. LANCET ONCOLOGY, 2011, 12 (02) : 127 - 136